Before initiating ocrelizumab therapy, hepatitis B virus screening is indicated.

Patients receiving an ocrelizumab infusion will require monitoring for at least the next hour for the following signs and symptoms of refusion reactions:

- Coughing or wheezing

- Dizziness

- Fast heart rate

- Fatigue

- Feeling faint

- Fever

- Flushing

- Headache

- Hives

- Itchy skin

- Nausea

- Rash

- Shortness of breath

- Swelling of throat

- Throat irritation or pain

- Tiredness

- Trouble breathing

In clinical trials, there was an incidence of life-threatening bronchospasm (which recovered with treatment) with the initial infusion of ocrelizumab.